ECSP13012460A - 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores KCNQ2/3 - Google Patents

2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores KCNQ2/3

Info

Publication number
ECSP13012460A
ECSP13012460A ECSP13012460A ECSP13012460A EC SP13012460 A ECSP13012460 A EC SP13012460A EC SP13012460 A ECSP13012460 A EC SP13012460A EC SP13012460 A ECSP13012460 A EC SP13012460A
Authority
EC
Ecuador
Prior art keywords
thioxo
dihydroquinoline
oxo
kcnq2
modulators
Prior art date
Application number
Other languages
English (en)
Inventor
Kühnert Sven
Bahrenberg Gregor
Kless Achim
Schröder Wolfgang
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of ECSP13012460A publication Critical patent/ECSP13012460A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La invención se refiere a o 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidas con composiciones farmacéuticas que contienen estos compuestos y también a estos compuestos para uso en el tratamiento y/o profilaxis del dolor y otras patologías y/o trastornos
ECSP13012460 2010-08-27 2013-02-26 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores KCNQ2/3 ECSP13012460A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10008920 2010-08-27

Publications (1)

Publication Number Publication Date
ECSP13012460A true ECSP13012460A (es) 2013-03-28

Family

ID=43304979

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012460 ECSP13012460A (es) 2010-08-27 2013-02-26 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores KCNQ2/3

Country Status (30)

Country Link
US (1) US8653102B2 (es)
EP (1) EP2609086B1 (es)
JP (1) JP5837934B2 (es)
KR (1) KR101983979B1 (es)
CN (1) CN103189357B (es)
AR (1) AR082731A1 (es)
AU (1) AU2011295408B2 (es)
BR (1) BR112013004690A2 (es)
CA (1) CA2809287C (es)
CL (1) CL2013000542A1 (es)
CO (1) CO6700825A2 (es)
CY (1) CY1116158T1 (es)
DK (1) DK2609086T3 (es)
EC (1) ECSP13012460A (es)
ES (1) ES2537615T3 (es)
HK (1) HK1185346A1 (es)
HR (1) HRP20150520T1 (es)
HU (1) HUE024870T2 (es)
IL (1) IL223820A (es)
MX (1) MX342459B (es)
NZ (1) NZ608697A (es)
PE (1) PE20140214A1 (es)
PL (1) PL2609086T3 (es)
PT (1) PT2609086E (es)
RS (1) RS54002B1 (es)
RU (1) RU2581362C2 (es)
SI (1) SI2609086T1 (es)
TW (1) TWI552750B (es)
WO (1) WO2012025239A1 (es)
ZA (1) ZA201302265B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537628T3 (es) * 2010-08-27 2015-06-10 Grünenthal GmbH 2-Oxiquinolin-3-carboxamidas sustituidas como moduladores de KCNQ2/3
WO2014056620A1 (en) * 2012-10-11 2014-04-17 Grünenthal GmbH Treatment and/or prophylaxis of tspo mediated diseases and/or disorders
WO2017120355A1 (en) * 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
US9975886B1 (en) * 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2513949A1 (de) 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
FR2482596A1 (fr) 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
DE3111934A1 (de) 1981-03-26 1982-10-07 Bayer Ag, 5090 Leverkusen Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung
FR2509728A1 (fr) 1981-07-17 1983-01-21 Roussel Uclaf Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
DE3210063A1 (de) 1982-03-19 1983-09-22 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
DE3211934A1 (de) 1982-03-31 1983-10-13 Hoechst Ag, 6230 Frankfurt Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
FR2532939A1 (fr) 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
US5359365A (en) 1991-05-24 1994-10-25 Canon Kabushiki Kaisha Moving image processing method and apparatus
US5525611A (en) 1993-06-04 1996-06-11 Behforouz; Mohammad Lavendamycin analogs and methods of making and using them
US6030983A (en) 1993-06-04 2000-02-29 Ball State University Lavendamycin analogs, quinoline-5,8-diones and methods of using them
EP0634169B1 (en) 1993-06-29 2000-01-05 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
WO1996026925A1 (fr) 1995-03-01 1996-09-06 Banyu Pharmaceutical Co., Ltd. Derives de l'arylthioacetamide
JPH08337583A (ja) * 1995-04-13 1996-12-24 Takeda Chem Ind Ltd 複素環化合物およびその製造法
DE19738616A1 (de) 1997-09-04 1999-03-11 Clariant Gmbh 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
GB9807114D0 (en) 1998-04-02 1998-06-03 Smithkline Beecham Plc Novel process
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2001010381A2 (en) 1999-08-04 2001-02-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
JP2003506387A (ja) 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド カリウムチャンネルオープナーとしてのベンズアニリド
CN100390148C (zh) 1999-10-25 2008-05-28 活跃生物技术有限公司 用于治疗恶性肿瘤的药物
KR20030070082A (ko) * 2000-12-28 2003-08-27 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
WO2002072088A2 (en) 2001-02-20 2002-09-19 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
CZ20032233A3 (cs) 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
US7087758B2 (en) 2001-04-06 2006-08-08 Smithkline Beecham Corporation Quinoline inhibitors of hyaki and hyak3 kinases
EP1542966A1 (en) 2002-09-17 2005-06-22 Pharmacia Corporation Aromatic liver x-receptor modulators
JP2006502190A (ja) 2002-09-18 2006-01-19 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ デルタ−オピオイド受容体に選択的なオピエート類似物
DE60335028D1 (de) 2002-12-23 2010-12-30 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
EP1449841A1 (en) 2003-02-19 2004-08-25 Bayer CropScience SA New fungicidal compounds
WO2004083184A1 (ja) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 受容体拮抗剤
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
DK1689742T3 (da) * 2003-11-24 2010-05-17 Pfizer Quinoloncarboxylsyreforbindelser med 5-HT-receptor-agonistisk aktivitet
AR048669A1 (es) 2004-03-03 2006-05-17 Syngenta Ltd Derivados biciclicos de bisamida
EA200601830A1 (ru) 2004-05-04 2007-04-27 Пфайзер Инк. Ортозамещённые арильные или гетероарильные амидные соединения
CA2585490A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
EP2298766B1 (en) 2005-03-03 2013-09-18 H. Lundbeck A/S Pharmaceutical formulations comrpising a substituted pyridine derivative
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
ATE432259T1 (de) 2005-07-20 2009-06-15 Lilly Co Eli Pyridinderivate als dipeptedyl-peptidase-hemmer
CN101277939A (zh) 2005-09-09 2008-10-01 布里斯托尔-迈尔斯斯奎布公司 无环ikur抑制剂
JP2009515934A (ja) 2005-11-18 2009-04-16 ノイロサーチ アクティーゼルスカブ 新規なキナゾリン誘導体及びこれらの医学的使用
WO2007070359A2 (en) 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
NZ610790A (en) 2006-04-13 2015-05-29 Nupathe Inc Transdermal methods and systems for the delivery of anti-migraine compounds
US7763607B2 (en) * 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
WO2007133637A2 (en) 2006-05-10 2007-11-22 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2008007211A1 (en) 2006-07-11 2008-01-17 Pfizer Japan Inc. Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
WO2008011110A2 (en) 2006-07-20 2008-01-24 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
DE602007004638D1 (de) 2006-07-20 2010-03-18 Amgen Inc Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
JP2009544732A (ja) 2006-07-26 2009-12-17 ノバルティス アクチエンゲゼルシャフト ウンデカプレニルピロホスフェートシンターゼの阻害剤
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
WO2008127274A2 (en) * 2006-09-22 2008-10-23 Ptc Therapeutics, Inc. Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
EP2222631B1 (en) 2006-10-23 2011-08-17 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
US20080221161A1 (en) 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
US9162984B2 (en) 2007-03-30 2015-10-20 University Of Rochester Small-molecule modulators of melanin expression
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
WO2009019149A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
CA2702469A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
US8119656B2 (en) * 2007-12-07 2012-02-21 The Board Of Regents Of The University Of Texas System Inhibitors of the influenza virus non-structural 1 protein
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
EP2344481B9 (en) 2008-09-23 2014-12-31 Georgetown University Viral and fungal inhibitors
BRPI0919898A2 (pt) 2008-10-24 2016-02-16 Gruenenthal Gmbh 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3
US8367700B2 (en) 2008-12-17 2013-02-05 Gruenenthal Gmbh Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators
WO2010094645A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094644A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
WO2010102778A2 (de) 2009-03-10 2010-09-16 Grünenthal GmbH Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
BR112013004721A2 (pt) 2010-08-27 2016-05-17 Gruenenthal Gmbh "quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3"
ES2537628T3 (es) * 2010-08-27 2015-06-10 Grünenthal GmbH 2-Oxiquinolin-3-carboxamidas sustituidas como moduladores de KCNQ2/3

Also Published As

Publication number Publication date
CN103189357B (zh) 2015-11-25
RU2013113301A (ru) 2014-10-10
RS54002B1 (en) 2015-10-30
JP2013536213A (ja) 2013-09-19
PE20140214A1 (es) 2014-02-19
MX2013002119A (es) 2013-04-03
TW201212917A (en) 2012-04-01
CA2809287A1 (en) 2012-03-01
AU2011295408A1 (en) 2013-04-11
HUE024870T2 (en) 2016-02-29
ES2537615T3 (es) 2015-06-10
AU2011295408B2 (en) 2015-05-14
EP2609086A1 (en) 2013-07-03
PL2609086T3 (pl) 2015-07-31
CL2013000542A1 (es) 2013-08-09
KR20130095755A (ko) 2013-08-28
ZA201302265B (en) 2021-05-26
NZ608697A (en) 2014-07-25
CA2809287C (en) 2018-05-22
WO2012025239A1 (en) 2012-03-01
MX342459B (es) 2016-09-29
BR112013004690A2 (pt) 2016-05-10
HRP20150520T1 (hr) 2015-07-03
PT2609086E (pt) 2015-06-30
KR101983979B1 (ko) 2019-05-30
US20120053206A1 (en) 2012-03-01
SI2609086T1 (sl) 2015-04-30
CN103189357A (zh) 2013-07-03
RU2581362C2 (ru) 2016-04-20
JP5837934B2 (ja) 2015-12-24
DK2609086T3 (da) 2015-03-30
TWI552750B (zh) 2016-10-11
EP2609086B1 (en) 2015-02-25
IL223820A (en) 2016-08-31
CY1116158T1 (el) 2017-02-08
CO6700825A2 (es) 2013-06-28
US8653102B2 (en) 2014-02-18
AR082731A1 (es) 2012-12-26
HK1185346A1 (en) 2014-02-14

Similar Documents

Publication Publication Date Title
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
GT201400111A (es) Triazolopiridinas sustituidas
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
ECSP15007358A (es) Pirrol carboxamidas fluorometilo sustituidas
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
NI201700078A (es) Pirazolpiridinaminas
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
ECSP13012460A (es) 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores KCNQ2/3
MX2018004217A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
BR112015016391A2 (pt) carboxamidas i baseadas em pirazolil como inibidoras do canal crac
MX2016007955A (es) Pirrol carboxamidas iii fluorometil-sustituidas.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.